Novo Nordisk A/S $NVO Stake Reduced by Knuff & Co LLC

Knuff & Co LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 32.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 171,750 shares of the company’s stock after selling 83,274 shares during the period. Novo Nordisk A/S makes up about 2.6% of Knuff & Co LLC’s holdings, making the stock its 10th biggest holding. Knuff & Co LLC’s holdings in Novo Nordisk A/S were worth $8,739,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Guerra Advisors Inc bought a new position in Novo Nordisk A/S during the 3rd quarter valued at about $25,000. WealthCollab LLC boosted its holdings in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: New data presented at the European Congress on Obesity showed higher-dose Wegovy helped early responders lose about 27.7% of body weight by week 72, with most of the loss coming from body fat and muscle largely preserved. Article Title
• Positive Sentiment: Additional Wegovy studies showed strong results in women across menopause stages, including substantial weight loss and potential cardiovascular, migraine, and depression benefits, supporting the company’s broader stock thesis. Article Title
• Positive Sentiment: Novo Nordisk said some patients on the Wegovy pill achieved 21.6% weight loss in a clinical trial, reinforcing optimism around its oral semaglutide pipeline and future obesity-market expansion. Article Title
• Positive Sentiment: Hedgeye reportedly added Novo Nordisk as a new long idea, reflecting improving market sentiment toward the shares. Article Title
• Neutral Sentiment: Articles highlighted that Novo Nordisk has been a long-term outperformer and that the stock is trending among investors, but these pieces are largely retrospective and do not add new fundamental information. Article Title
• Negative Sentiment: Some commentary warned that Novo Nordisk’s low P/E may be a value trap, and competitive pressure in GLP-1 drugs remains intense as Eli Lilly pushes next-generation obesity treatments. Article Title

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $47.13 on Thursday. The firm’s 50 day moving average price is $39.42 and its 200-day moving average price is $46.76. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $210.41 billion, a PE ratio of 11.06, a price-to-earnings-growth ratio of 4.19 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.47 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on NVO shares. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a report on Tuesday, March 10th. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.